EP0650370A4 - METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUES. - Google Patents
METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUES.Info
- Publication number
- EP0650370A4 EP0650370A4 EP93914334A EP93914334A EP0650370A4 EP 0650370 A4 EP0650370 A4 EP 0650370A4 EP 93914334 A EP93914334 A EP 93914334A EP 93914334 A EP93914334 A EP 93914334A EP 0650370 A4 EP0650370 A4 EP 0650370A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- specific tissues
- targeting specific
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90609292A | 1992-06-08 | 1992-06-08 | |
| US906092 | 1992-06-08 | ||
| PCT/US1993/005260 WO1993025234A1 (en) | 1992-06-08 | 1993-06-03 | Methods and compositions for targeting specific tissue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0650370A1 EP0650370A1 (en) | 1995-05-03 |
| EP0650370A4 true EP0650370A4 (en) | 1995-11-22 |
Family
ID=25421920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP93914334A Withdrawn EP0650370A4 (en) | 1992-06-08 | 1993-06-03 | METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUES. |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0650370A4 (en) |
| JP (1) | JPH07507689A (en) |
| WO (1) | WO1993025234A1 (en) |
Families Citing this family (286)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU688292B2 (en) | 1992-11-09 | 1998-03-12 | United States Government as represented by the Department of Health and Human Services, The | Targetable vector particles |
| GB9402857D0 (en) | 1994-02-15 | 1994-04-06 | Isis Innovation | Targeting gene therapy |
| US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
| GB9412844D0 (en) * | 1994-06-27 | 1994-08-17 | Medical Res Council | Improvements in or relating to therapeutic methods |
| US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| JPH11510050A (en) * | 1995-07-25 | 1999-09-07 | イントロヘーネ ベスローテン フェンノートシャップ | Methods and means for targeted gene delivery |
| GB9519776D0 (en) * | 1995-09-28 | 1995-11-29 | Casimir Colin | Materials and methods relating to the transfer of nucleic acid into stem cells |
| EP0880596A1 (en) * | 1995-12-28 | 1998-12-02 | Chiron Corporation | Receptor specific chimeric viral surface polypeptides for viral and particle incorporation and internalization in target cells |
| DE19605279A1 (en) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Target cell-specific vectors for the introduction of genes into cells, drugs containing such vectors and their use |
| CA2266656A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| EP2008664B1 (en) | 1997-04-10 | 2012-08-29 | University Of Southern California | Modified proteins which bind extracellular matrix components |
| US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
| US6162641A (en) * | 1997-06-06 | 2000-12-19 | The Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
| EP1002103B1 (en) | 1997-08-04 | 2007-10-17 | Cell Genesys, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
| JP2002516061A (en) | 1997-10-14 | 2002-06-04 | ダーウィン モレキュラー コーポレイション | Mutants of thymidine kinase and fusion proteins having thymidine kinase activity and guanylate kinase activity |
| ATE476508T1 (en) | 1997-11-06 | 2010-08-15 | Novartis Vaccines & Diagnostic | NEISSERIAL ANTIGENS |
| SG152917A1 (en) | 1998-01-14 | 2009-06-29 | Chiron Srl | Neisseria meningitidis antigens |
| US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| EP2261341A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| EP0960942A3 (en) * | 1998-05-20 | 2000-01-12 | Introgene B.V. | Targeted delivery through a cationic amino acid transporter |
| EP0959136A1 (en) * | 1998-05-20 | 1999-11-24 | Introgene B.V. | Targeted delivery through a cationic amino acid transporter |
| EP0972841A1 (en) * | 1998-05-20 | 2000-01-19 | Introgene B.V. | Display of viral proteins as ligands for cell-surface receptor |
| EP0959135A1 (en) * | 1998-05-20 | 1999-11-24 | Introgene B.V. | Display of viral proteins and targeted delivery to cellular receptor |
| DE69938190T2 (en) | 1998-10-15 | 2009-03-05 | Novartis Vaccines and Diagnostics, Inc., Emeryville | GENES WITH CHANGED EXPRESSION IN METASTIC BREAST OR THICK-DARM CANCER CELLS |
| US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| JP2003524389A (en) | 1998-12-16 | 2003-08-19 | カイロン コーポレイション | Human cyclin dependent kinase (hPNQALRE) |
| US7063850B1 (en) | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
| US6911429B2 (en) | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| US7396905B1 (en) | 1999-05-21 | 2008-07-08 | Mckeon Frank | Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| EP2275552B1 (en) | 1999-10-29 | 2015-09-09 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
| DE60043197D1 (en) | 1999-11-18 | 2009-12-03 | Univ Kyoto | |
| US8168178B2 (en) | 1999-11-30 | 2012-05-01 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| US6951839B1 (en) | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| EP1854476A3 (en) | 2000-02-09 | 2008-05-07 | Bas Medical, Inc. | Use of relaxin to treat diseases related to vasoconstriction |
| EP1261638A2 (en) | 2000-03-08 | 2002-12-04 | Chiron Corporation | Human fgf-23 gene and gene expression products |
| EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| WO2003057926A1 (en) | 2002-01-08 | 2003-07-17 | Chiron Corporation | Gene products differentially expressed in cancerous breast cells and their methods of use |
| ES2305087T3 (en) | 2000-06-15 | 2008-11-01 | Novartis Vaccines And Diagnostics, Inc. | POLINUCLEOTIDOS RELATED TO CANCER DE COLON. |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| JP2004535765A (en) | 2000-12-07 | 2004-12-02 | カイロン コーポレイション | Endogenous retrovirus up-regulated in prostate cancer |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| NZ527591A (en) | 2001-01-17 | 2006-04-28 | Trubion Pharmaceuticals Inc | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
| EP1478751A4 (en) | 2001-03-30 | 2005-10-19 | Avigenics Inc | Avian lysozyme promoter |
| US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
| WO2002081639A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
| WO2002081642A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
| AU2002305151A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
| JP4353701B2 (en) | 2001-05-08 | 2009-10-28 | ダーウィン モレキュラー コーポレイション | Method for regulating immune function in primates using FOXP3 protein |
| JP4302513B2 (en) | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Polynucleotides encoding antigenic type B HIV polypeptides and / or antigenic type C HIV polypeptides, polypeptides thereof and uses thereof |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
| US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
| CA2464527A1 (en) | 2001-10-26 | 2003-08-14 | Id Biomedical Corporation Of Washington | Multivalent streptococcal vaccine compositions and methods for use |
| RU2316591C2 (en) | 2001-11-09 | 2008-02-10 | Джорджтаун Юниверсити | New isoforms of vascular endothelial cell growth inhibitor |
| US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| ES2312649T3 (en) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | IMMUNIZATION AGAINST CHLAMYDIA TRACHOMATIS. |
| US7255874B1 (en) | 2001-12-21 | 2007-08-14 | Closure Medical Corporation | Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto |
| US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
| US7615229B2 (en) | 2002-03-15 | 2009-11-10 | Wyeth Holdings Corporation | Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity |
| EP2093233A1 (en) | 2002-03-21 | 2009-08-26 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
| US7138512B2 (en) | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
| JP2005535308A (en) | 2002-06-13 | 2005-11-24 | カイロン コーポレイション | HML-2 polypeptide expression vector |
| CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| JP4584713B2 (en) | 2002-10-08 | 2010-11-24 | ライナット ニューロサイエンス コーポレイション | Methods for treating postoperative pain by administering a nerve growth factor antagonist and compositions containing the nerve growth factor antagonist |
| WO2005000194A2 (en) | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| CN101014364B (en) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | Anti-NGF antibodies and methods of use thereof |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US20070149449A1 (en) | 2003-02-14 | 2007-06-28 | Morris David W | Therapeutic targets in cancer |
| US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
| PL379983A1 (en) | 2003-02-19 | 2006-11-27 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| ES2366617T3 (en) | 2003-04-21 | 2011-10-21 | Epeius Biotechnologies Corporation | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS. |
| US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| US9532994B2 (en) | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| AU2004308482A1 (en) | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
| EP1736541B1 (en) | 2004-03-29 | 2013-01-23 | Galpharma Co., Ltd. | Novel modified galectin 9 protein and use thereof |
| EP3372614B1 (en) | 2004-04-07 | 2022-06-08 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| WO2006007377A2 (en) | 2004-06-16 | 2006-01-19 | The General Hospital Corporation | Methods of screening for bridge-1-mediated disorders, including type ii diabetes |
| PT1789593T (en) | 2004-07-09 | 2017-04-24 | Henry M Jackson Found Advancement Military Medicine Inc | Soluble forms of hendra virus g glycoprotein |
| AU2005275062A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utah Research Foundation | Netrin-related compositions and uses |
| US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
| MX2007000998A (en) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same. |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| JP2008535857A (en) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | CACNA1E in cancer diagnosis, detection and treatment |
| JP2008535853A (en) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | Cancer-related genes |
| US7462698B2 (en) | 2005-07-22 | 2008-12-09 | Y's Therapeutics Co., Ltd. | Anti-CD26 antibodies and methods of use thereof |
| HUE026303T2 (en) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| KR20080068062A (en) | 2005-11-14 | 2008-07-22 | 리나트 뉴로사이언스 코퍼레이션 | Antagonist antibodies directed against calcitonin gene-related peptides and methods of use thereof |
| CA2637707A1 (en) | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corporation | Methods for treating obesity by administering a trkb antagonist |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| DK2044120T3 (en) | 2006-06-07 | 2019-04-15 | Bioalliance Cv | ANTIBODIES THAT RECOGNIZE A CARBOHYDRATE-CONTAINING EPITOP ON CD-43 AND CEA EXPRESSED ON CANCER CELLS, AND METHODS FOR USING IT |
| WO2008020335A2 (en) | 2006-06-09 | 2008-02-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
| CN105837690A (en) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | Single-chain multivalent binding proteins with effector function |
| WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US8273361B2 (en) | 2006-09-26 | 2012-09-25 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US8664364B2 (en) | 2007-01-24 | 2014-03-04 | Carnegie Mellon University | Optical biosensors |
| AU2008331808B2 (en) | 2007-03-16 | 2014-08-21 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| WO2008116116A2 (en) | 2007-03-20 | 2008-09-25 | Harold Brem | Gm-csf cosmeceutical compositions and methods of use thereof |
| US20100261640A1 (en) | 2007-04-10 | 2010-10-14 | Branco Luis M | Soluble and membrane anchored forms of lassa virus subunit proteins |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| BRPI0822049B1 (en) | 2007-12-17 | 2021-11-16 | Pfizer Limited | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-NGF ANTAGONIST ANTIBODY, KIT AND USE OF AN ANTINGF ANTIBODY |
| AU2008338313B2 (en) | 2007-12-18 | 2014-01-16 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
| CA2718975A1 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
| AU2009234277B2 (en) | 2008-04-11 | 2014-12-04 | Aptevo Research And Development Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US7928189B2 (en) | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
| WO2010039536A2 (en) | 2008-09-23 | 2010-04-08 | President And Fellows Of Harvard College | Sirt4 and uses thereof |
| US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
| EP2379720B1 (en) | 2009-01-20 | 2016-08-17 | Alona Zilberberg | Mir-21 promoter driven targeted cancer therapy |
| US9719069B2 (en) | 2009-01-27 | 2017-08-01 | University Of Utah Research Foundation | Methods and compositions relating to viral latency |
| WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
| US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
| EP2408904B1 (en) | 2009-03-20 | 2017-10-18 | Mesoblast, Inc. | Production of reprogrammed pluripotent cells |
| WO2010118243A2 (en) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Use of il-27 antagonists to treat lupus |
| CA2758490C (en) | 2009-04-14 | 2023-05-02 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| CA2760042C (en) | 2009-04-27 | 2020-03-10 | Ottawa Hospital Research Institute | Compositions and methods for modulating stem cells and uses thereof |
| LT2437753T (en) | 2009-06-05 | 2016-12-12 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
| WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
| HRP20141270T1 (en) | 2009-07-16 | 2015-03-13 | Novartis Ag | DETOXIFIED IMMUNOGENIC ESCHERICHIE COLI |
| US8563261B2 (en) | 2009-09-28 | 2013-10-22 | The Trustees Of The University Of Pennsylvania | Method of diagnosing and treating interstitial cystitis |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| CA2787628A1 (en) | 2010-01-21 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Context specific genetic screen platform to aid in gene discovery and target validation |
| US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| CN105218674A (en) | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | The antibody combined in pH dependence antigen |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
| JP2013533286A (en) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | How to treat pain |
| WO2012064743A2 (en) | 2010-11-08 | 2012-05-18 | The Johns Hopkins University | Methods for improving heart function |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| EP2663868A2 (en) | 2010-12-01 | 2013-11-20 | The University of North Carolina at Chapel Hill | Methods and compositions for targeting sites of neovascular growth |
| JP6228010B2 (en) | 2010-12-27 | 2017-11-08 | ブラウン ユニバーシティ | Treatment and diagnostic methods for biglycan and utrophin |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US20130071375A1 (en) | 2011-08-22 | 2013-03-21 | Saint Louis University | Compositions and methods for treating inflammation |
| WO2013028527A1 (en) | 2011-08-23 | 2013-02-28 | Indiana University Research And Technology Corporation | Compositions and methods for treating cancer |
| WO2013039996A1 (en) | 2011-09-13 | 2013-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using fndc5 |
| WO2013055911A1 (en) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Znf365/zfp365 biomarker predictive of anti-cancer response |
| HK1201851A1 (en) | 2011-11-11 | 2015-09-11 | 瑞纳神经科学公司 | Antibodies specific for trop-2 and their uses |
| WO2013093707A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Human growth hormone receptor antagonist antibodies and methods of use thereof |
| WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
| US11510875B2 (en) | 2012-02-07 | 2022-11-29 | Access To Advanced Health Institute | Adjuvant formulations comprising TLR4 agonists and methods of using the same |
| NZ701324A (en) | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| RU2632191C2 (en) | 2012-05-07 | 2017-10-03 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Oxy133 OXYSTEROL ANALOGUE INDUCTS OSTEOGENESIS AND SIGNAL WAY HEDGEHOG AND INHIBITED LIPOGENESIS |
| LT2850431T (en) | 2012-05-16 | 2018-06-25 | Immune Design Corp. | Vaccines for hsv-2 |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| AU2013343099A1 (en) | 2012-11-09 | 2015-05-14 | Pfizer Inc. | Platelet-derived growth factor B specific antibodies and compositions and uses thereof |
| EP2970945B1 (en) | 2013-03-14 | 2024-05-01 | GenVivo, Inc. | Improved thymidine kinase gene |
| EP2970502A4 (en) | 2013-03-15 | 2016-11-30 | Dyax Corp | Anti-plasma kallikrein antibodies |
| KR102039520B1 (en) | 2013-04-18 | 2019-11-01 | 이뮨 디자인 코포레이션 | GLA monotherapy for use in cancer treatment |
| CA2911205A1 (en) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
| WO2014181229A2 (en) | 2013-05-07 | 2014-11-13 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| EP3008043A2 (en) | 2013-06-14 | 2016-04-20 | University Of Utah Research Foundation | Triazol-1-ol analogs anti-retroviral latency drugs |
| EP3044314B1 (en) | 2013-07-12 | 2019-04-10 | SeNa Research, Inc. | Methods and compositions for interference with dna polymerase and dna synthesis |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| WO2015015401A2 (en) | 2013-08-02 | 2015-02-05 | Pfizer Inc. | Anti-cxcr4 antibodies and antibody-drug conjugates |
| CA2929784C (en) | 2013-11-13 | 2019-11-26 | Pfizer Inc. | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
| WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| US11624093B2 (en) | 2014-04-24 | 2023-04-11 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| WO2015168474A1 (en) | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
| CA2947605A1 (en) | 2014-05-13 | 2015-11-19 | Bioatla, Llc | Conditionally active biological proteins |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| EP3186284B1 (en) | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| US10513699B2 (en) | 2014-09-03 | 2019-12-24 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| MX2017003062A (en) | 2014-09-09 | 2017-12-14 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy. |
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| WO2016057651A1 (en) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
| TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-PD-1 antibodies and methods of using same |
| EP3240570B1 (en) | 2015-01-02 | 2025-09-24 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and factor xii |
| CA2977532A1 (en) | 2015-03-06 | 2016-09-15 | Dana-Farber Cancer Institute, Inc. | Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers |
| US20180042998A1 (en) | 2015-03-10 | 2018-02-15 | University Of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
| US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
| ES3012402T3 (en) | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| WO2017015334A1 (en) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
| EA201890340A1 (en) | 2015-07-21 | 2018-09-28 | Дайэкс Корп. | MONOCLONAL ANTIBODY-INHIBITOR OF FACTOR XIIA |
| EP3325010B1 (en) | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Antibodies to coagulation factor xia and uses thereof |
| PE20240142A1 (en) | 2015-08-19 | 2024-02-01 | Pfizer | INHIBITORY ANTIBODIES VIA TISSUE FACTOR AND USES THEREOF |
| RS62330B1 (en) | 2015-09-15 | 2021-10-29 | Scholar Rock Inc | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| EP4265633A3 (en) | 2015-10-16 | 2024-01-24 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| EP3365369A1 (en) | 2015-10-23 | 2018-08-29 | Pfizer Inc | Anti-il-2 antibodies and compositions and uses thereof |
| WO2017075037A1 (en) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Primed growth factors and uses thereof |
| EP3368157B1 (en) | 2015-10-29 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
| CN106699889A (en) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | PD-1 resisting antibody and treatment application thereof |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| DK3405490T3 (en) | 2016-01-21 | 2022-01-10 | Pfizer | MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF |
| KR20190080825A (en) | 2016-03-21 | 2019-07-08 | 다나-파버 캔서 인스티튜트 인크. | T-cell dysfunction state-specific gene expression regulators and their uses |
| JP7051715B2 (en) | 2016-05-13 | 2022-04-11 | バイオアトラ、エルエルシー | Anti-Ror2 antibodies, antibody fragments, their immune conjugates and their use |
| HUE059605T2 (en) | 2016-05-16 | 2022-11-28 | Access To Advanced Health Inst | Formulation containing tlr agonist and methods of use |
| JP7140684B2 (en) | 2016-06-01 | 2022-09-21 | アクセス ツー アドバンスト ヘルス インスティチュート | Nano Alum Particles Containing Sizing Agent |
| US20180030478A1 (en) | 2016-07-01 | 2018-02-01 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
| US11136409B2 (en) | 2016-09-20 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators |
| US20180119141A1 (en) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
| WO2018148246A1 (en) | 2017-02-07 | 2018-08-16 | Massachusetts Institute Of Technology | Methods and compositions for rna-guided genetic circuits |
| BR112019017500A2 (en) | 2017-03-03 | 2020-04-14 | Rinat Neuroscience Corp | anti-gitr antibodies and methods of using them |
| CA3056182A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
| AU2018250695A1 (en) | 2017-04-14 | 2019-11-07 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
| EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
| EP3634496A4 (en) | 2017-06-06 | 2021-09-08 | Dana-Farber Cancer Institute, Inc. | METHOD FOR RISING AWARENESS IN CANCER CELLS AGAINST T-CELL-MEDIATED KILLING BY MODULATING MOLECULAR SIGNAL PATHS |
| US20180357361A1 (en) | 2017-06-13 | 2018-12-13 | Feliks Frenkel | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
| WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | Anti-nucleolin antibody |
| WO2019056015A2 (en) | 2017-09-18 | 2019-03-21 | Children's Hospital Medical Center | A strong insulator and uses thereof in gene delivery |
| JP2020536115A (en) | 2017-10-04 | 2020-12-10 | オプコ ファーマシューティカルズ、エルエルシー | Articles and methods for personalized cancer therapy |
| WO2019084343A1 (en) | 2017-10-25 | 2019-05-02 | The Administrators Of The Tulane Educational Fund | Peptide compositions and methods of use thereof |
| ES3032734T3 (en) | 2017-10-27 | 2025-07-24 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
| CN112020518A (en) | 2018-02-01 | 2020-12-01 | 辉瑞公司 | Chimeric Antigen Receptor Targeting CD70 |
| PE20251579A1 (en) | 2018-02-01 | 2025-06-16 | Pfizer | CD70-SPECIFIC ANTIBODIES AND THEIR USES |
| KR20200128116A (en) | 2018-02-28 | 2020-11-11 | 화이자 인코포레이티드 | IL-15 variants and uses thereof |
| US20210032334A1 (en) | 2018-02-28 | 2021-02-04 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents |
| BR112020017872A2 (en) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES OF THE SAME |
| BR112020015999A2 (en) | 2018-04-06 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | KIR3DL3 AS A HHLA2 RECEPTOR, ANTI-HHLA2 ANTIBODIES AND USES OF THE SAME |
| DK3797121T3 (en) | 2018-05-23 | 2024-07-08 | Pfizer | Antibodies specific for CD3 and uses thereof |
| KR20230146098A (en) | 2018-05-23 | 2023-10-18 | 화이자 인코포레이티드 | Antibodies specific for gucy2c and uses thereof |
| EP3817763B1 (en) | 2018-07-03 | 2025-09-03 | SOTIO Biotech Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| CN112840019B (en) | 2018-08-14 | 2025-07-04 | Sotio有限责任公司 | Chimeric antigen receptor polypeptides combined with trans-metabolism molecules regulating the Krebs cycle and their therapeutic uses |
| SG11202101994XA (en) | 2018-08-28 | 2021-03-30 | Vor Biopharma Inc | Genetically engineered hematopoietic stem cells and uses thereof |
| CN112805301B (en) | 2018-10-15 | 2023-07-21 | 安立玺荣生医(香港)有限公司 | Antibodies to granulocyte-macrophage colony-stimulating factor and uses thereof |
| JP7575102B2 (en) | 2018-12-21 | 2024-10-29 | マルチチュード インコーポレーテッド | MUC18-specific antibodies |
| CN114144190B (en) | 2019-01-23 | 2025-08-08 | 纽约大学 | Antibodies specific for the delta 1 chain of the T cell receptor |
| EP3721896B1 (en) | 2019-04-08 | 2023-11-29 | Giuseppe Scalabrino | Epidermal growth factor (egf) and variants thereof for treating or preventing inflammatory demyelinating disorders |
| US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
| EP3994696B1 (en) | 2019-07-03 | 2025-05-14 | BostonGene Corporation | Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control |
| EP4041308A1 (en) | 2019-10-07 | 2022-08-17 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4041773A1 (en) | 2019-10-11 | 2022-08-17 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
| US20230067811A1 (en) | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
| EP4093513A4 (en) | 2020-01-24 | 2024-05-08 | Dana-Farber Cancer Institute, Inc. | Uses of biomarkers for improving immunotherapy |
| WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| EP4146688A1 (en) | 2020-05-06 | 2023-03-15 | CRISPR Therapeutics AG | Mask peptides and masked anti-ptk7 antibodies comprising such |
| EP4165071A4 (en) | 2020-06-15 | 2024-07-17 | Academia Sinica | HUMANIZED ACE2-FC FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION |
| JP2023533793A (en) | 2020-07-17 | 2023-08-04 | ファイザー・インク | Therapeutic antibodies and their uses |
| US20230287455A1 (en) | 2020-07-30 | 2023-09-14 | Pfizer Inc. | Cells Having Gene Duplications and Uses Thereof |
| US20230374599A1 (en) | 2020-10-19 | 2023-11-23 | Alexander Gusev | Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
| WO2022104104A2 (en) | 2020-11-13 | 2022-05-19 | Dana-Farber Cancer Institute, Inc. | Personalized fusion cell vaccines |
| WO2022120256A2 (en) | 2020-12-04 | 2022-06-09 | Bostongene Corporation | Hierarchical machine learning techniques for identifying molecular categories from expression data |
| WO2022159793A2 (en) | 2021-01-25 | 2022-07-28 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for identifying neuroendocrine prostate cancer |
| EP4330969A1 (en) | 2021-04-29 | 2024-03-06 | BostonGene Corporation | Machine learning techniques for estimating tumor cell expression in complex tumor tissue |
| WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
| JP2024528139A (en) | 2021-08-02 | 2024-07-26 | ファイザー・インク | Improved expression vectors and uses thereof |
| EP4408982A1 (en) | 2021-09-27 | 2024-08-07 | SOTIO Biotech Inc. | Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof |
| EP4433515A1 (en) | 2021-11-16 | 2024-09-25 | SOTIO Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| EP4440594A2 (en) | 2021-11-29 | 2024-10-09 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
| US20230245479A1 (en) | 2022-01-31 | 2023-08-03 | Bostongene Corporation | Machine learning techniques for cytometry |
| WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
| CA3249166A1 (en) | 2022-02-16 | 2023-08-24 | Univ Johns Hopkins | Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof |
| WO2024015561A1 (en) | 2022-07-15 | 2024-01-18 | Bostongene Corporation | Techniques for detecting homologous recombination deficiency (hrd) |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
| WO2024040208A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| WO2025034542A1 (en) | 2023-08-04 | 2025-02-13 | Cornell University | Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy |
| WO2025096811A1 (en) | 2023-10-31 | 2025-05-08 | Bostongene Corporation | Machine learning technique for identifying ici responders and non-responders |
| US20250253011A1 (en) | 2024-02-02 | 2025-08-07 | Seven Bridges Genomics Inc. | Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
| WO1993022433A2 (en) * | 1992-04-28 | 1993-11-11 | Frank Andreas Harald Meyer | Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament |
-
1993
- 1993-06-03 JP JP6501565A patent/JPH07507689A/en active Pending
- 1993-06-03 EP EP93914334A patent/EP0650370A4/en not_active Withdrawn
- 1993-06-03 WO PCT/US1993/005260 patent/WO1993025234A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
| WO1993022433A2 (en) * | 1992-04-28 | 1993-11-11 | Frank Andreas Harald Meyer | Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament |
Non-Patent Citations (8)
| Title |
|---|
| ADV. EXP. MED. BIOL. (1988), 241(MOL. BIOL. HEMOPOIESIS), 19-27 CODEN: AEMBAP;ISSN: 0065-2598 * |
| CHEMICAL ABSTRACTS, vol. 111, no. 13, 25 September 1989, Columbus, Ohio, US; abstract no. 110248, EGLITIS, MARTIN A. ET AL: "Retroviral-mediated gene transfer into hemopoietic cells" * |
| DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; * |
| KASAHARA N. ET AL.: "TARGETED GENE DELIVERY BY RETROVIRUSES WITH PEPTIDE HORMONE SEQUENCES INCORPORATED INTO THE ENVELOPE.", J. CELL BIOCHEM. SUPPL., vol. 0, pages 237 * |
| LI, JING PO ET AL: "Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor", NATURE (LONDON) (1990), 343(6260), 762-4 CODEN: NATUAS;ISSN: 0028-0836 * |
| RANDY A. HOCK ET AL.: "RETROVIRUS-MEDIATED TRANSFER AND EXPRESSION OF DRUG RESISTANCE GENES IN HUMAN HAEMATOPOIETIC PROGENITOR CELLS.", NATURE, vol. 320, 20 March 1986 (1986-03-20), LONDON GB, pages 275 - 277 * |
| See also references of WO9325234A1 * |
| YOSHIMURA, AKIHIKO ET AL: "Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism", PROC. NATL. ACAD. SCI. U. S. A. (1990), 87(11), 4139-43 CODEN: PNASA6;ISSN: 0027-8424 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07507689A (en) | 1995-08-31 |
| EP0650370A1 (en) | 1995-05-03 |
| WO1993025234A1 (en) | 1993-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0650370A4 (en) | METHODS AND COMPOSITIONS FOR TARGETING SPECIFIC TISSUES. | |
| EP0659211A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MUCOVISCIDOSIS. | |
| EP1005330A4 (en) | METHODS AND COMPOSITIONS FOR TARGETING COMPOUNDS TO MUSCLES | |
| DE69519211D1 (en) | Forward controlled amplifier | |
| GB2297443B (en) | Amplifier | |
| EP0954302A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS INCLUDING ISOFLAVONES | |
| GB9814400D0 (en) | Amplifier circuitry | |
| EP0667870A4 (en) | COMPOSITIONS AND METHODS FOR ALTERING THE REGULATORY ACTIVITY OF TISSUE GROWTH FACTOR - g (b) (TGF - g (b)). | |
| DK0792574T3 (en) | Trailed implement | |
| GB9516025D0 (en) | Amplifier | |
| GB2308697B (en) | Sense amplifier | |
| FI963582A7 (en) | Amplifier | |
| BR9709971A (en) | Ozone-induced gene expression in plants | |
| DE69523890D1 (en) | Z-buffer device for suppressing hidden surfaces | |
| GB9519233D0 (en) | Amplifier arrangements | |
| GB9618138D0 (en) | Amplifier arrangements | |
| KR960006719U (en) | Dap Sowing Machine | |
| EP0931091A4 (en) | PLA 2 INHIBITORS | |
| KR960000001U (en) | Narrow plow | |
| KR960006020U (en) | Cash drawer | |
| KR960010006U (en) | Currency sterilizer | |
| DE59606869D1 (en) | Tillage implement | |
| BR9501580A (en) | Sowing implement | |
| BR9400109A (en) | Horticulture seeder | |
| FI952544A0 (en) | Plow |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19941124 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19951006 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| RHK1 | Main classification (correction) |
Ipc: A61K 39/12 |
|
| 17Q | First examination report despatched |
Effective date: 19980605 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19991125 |